Nuvilex Inc. (NASDAQ:PMCB – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 70,104 shares, a drop of 47.6% from the September 30th total of 133,885 shares. Based on an average trading volume of 99,423 shares, the short-interest ratio is currently 0.7 days. Approximately 0.7% of the company’s shares are sold short.
Nuvilex Stock Performance
Shares of Nuvilex stock traded up $0.01 during trading hours on Monday, reaching $0.31. The stock had a trading volume of 40,844 shares, compared to its average volume of 71,349. Nuvilex has a 1 year low of $0.30 and a 1 year high of $1.51. The firm has a 50 day simple moving average of $0.42 and a two-hundred day simple moving average of $0.64.
Nuvilex (NASDAQ:PMCB – Get Free Report) last posted its earnings results on Monday, September 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.48).
Analyst Ratings Changes
Separately, Weiss Ratings lowered shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.
Check Out Our Latest Analysis on PMCB
About Nuvilex
Nuvilex, Inc was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc and continued to trade under the ticker symbol PMCB. The company focused on developing cellular therapies intended to treat serious diseases, particularly cancer and diabetes.
Its primary technology involved encapsulating genetically engineered human cells in proprietary cellulose-based capsules. These cells were designed to produce therapeutic substances inside the body while limiting exposure to healthy tissue.
See Also
- Five stocks we like better than Nuvilex
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
